KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Intangibles (2016 - 2024)

CRISPR Therapeutics AG (CRSP) has disclosed Intangibles for 10 consecutive years, with $2000.0 as the latest value for Q1 2024.

  • Quarterly Intangibles fell 96.49% to $2000.0 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $2000.0 through Mar 2024, down 96.49% year-over-year, with the annual reading at $16000.0 for FY2023, 77.46% down from the prior year.
  • Intangibles hit $2000.0 in Q1 2024 for CRISPR Therapeutics AG, down from $16000.0 in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $221000.0 in Q1 2020 to a low of $2000.0 in Q1 2024.
  • Historically, Intangibles has averaged $111764.7 across 5 years, with a median of $112000.0 in 2022.
  • Biggest five-year swings in Intangibles: dropped 19.93% in 2020 and later crashed 96.49% in 2024.
  • Year by year, Intangibles stood at $180000.0 in 2020, then tumbled by 30.56% to $125000.0 in 2021, then plummeted by 43.2% to $71000.0 in 2022, then plummeted by 77.46% to $16000.0 in 2023, then crashed by 87.5% to $2000.0 in 2024.
  • Business Quant data shows Intangibles for CRSP at $2000.0 in Q1 2024, $16000.0 in Q4 2023, and $30000.0 in Q3 2023.